HSBC Holdings’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
Other funds holding ACAD
BBA
HSBC Holdings's ACAD Position: Q3 2026 in Review
HSBC Holdings increased its Acadia Pharmaceuticals (ACAD) stake by 31% in Q3 2026, buying an estimated $319K and bringing the position to 50,747 shares worth $1.03M. The position accounts for ﹤0.01% of the portfolio, ranked #1923.
HSBC Holdings first reported a position in ACAD in Q4 2017 and has held it in 23 quarters since. The position peaked at $1.27M in Q4 2024. 350 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.
- HSBC Holdings held 50,747 shares of Acadia Pharmaceuticals worth $1.03M as of Q3 2026.
- HSBC Holdings bought 11,885 Acadia Pharmaceuticals shares in Q3 2026, an estimated $319K.
- Acadia Pharmaceuticals made up ﹤0.01% of HSBC Holdings's portfolio in Q3 2026, its #1923 holding.
- HSBC Holdings first reported a position in Acadia Pharmaceuticals in Q4 2017 and has held it in 23 quarters since.
- HSBC Holdings's Acadia Pharmaceuticals position peaked at $1.27M in Q4 2024.
- 350 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.
Based on HSBC Holdings's 13F filing for Q3 2026, filed 16 Nov 2026.